Pasireotide in Hyperinsulinemic Hypoglycemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-30

Study Completion Date

2018-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a small controlled pilot study to assess the effect of subcutaneous pasireotide on preventing hypoglycemia due to hyperinsulinism, including congenital hyperinsulinism and insulinoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia

NCT02700048

Hypoglycemia Unawareness Type 1 Diabetes

TERMINATED PHASE1/PHASE2

Safety Study to Assess Whether Proinsulin Peptide Injections Can Slow or Stop the Body Damaging Its Own Insulin-making Cells in the Pancreas in Patients Newly Diagnosed With Type 1 Diabetes

NCT01536431

Type 1 Diabetes

COMPLETED PHASE1/PHASE2

Prevention of Severe Hypoglycemia in Type 1 Diabetes

NCT00360984

Type 1 Diabetes Mellitus

COMPLETED PHASE4

A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps

NCT02703324

Diabetes Mellitus, Type 1

COMPLETED PHASE1

IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase

NCT04028960

Type1diabetes

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pasireotide is a somatostatin analog with affinity for several somatostatin receptors including those on pancreatic beta cells; when activated these receptors affect the secretion of glucagon and insulin. Pasireotide is also known to decrease glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) secretion. Hyperglycemia is a well-documented adverse effect of pasireotide in its approved indications for treatment of Cushing's disease and acromegaly.

In light of this, the investigators hypothesize that pasireotide may be an effective therapy for hypoglycemia due to hyperinsulinism. Therefore a small controlled pilot study to assess the effect of subcutaneous (s.c.) pasireotide on preventing hypoglycemia due to hyperinsulinism over 7 hours of observation in both fasting and fed states is proposed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital Hyperinsulinism Insulinoma Hyperinsulinism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Normal saline s.c. injection once

Group Type PLACEBO_COMPARATOR

Saline Solution

Intervention Type DRUG

Saline Solution injection will be given once per study visit

Pasireotide

Pasireotide 0.6mg s.c. once

Group Type EXPERIMENTAL

Pasireotide 0.6Mg Solution for Injection

Intervention Type DRUG

Pasireotide 0.6Mg Solution for Injection will be given once per study visit

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pasireotide 0.6Mg Solution for Injection

Pasireotide 0.6Mg Solution for Injection will be given once per study visit

Intervention Type DRUG

Saline Solution

Saline Solution injection will be given once per study visit

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SOM230 Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patients aged 18 to 70 years old
2. Patients with hyperinsulinemic hypoglycemia due to either congenital hyperinsulinemic hypoglycemia or insulinoma, as determined by an endocrinologist
3. If no prior diagnosis of either insulinoma or congenital hyperinsulinemic hypoglycemia by an endocrinologist, the participant must meet the following criteria:

* A history of symptoms of hypoglycemia, (with or without a blood glucose \<50mg/dL at time of symptoms)
* Improvement of symptoms with ingestion of carbohydrates
* At least one documented blood glucose \<50mg/dL with concomitant insulin \>3 mmol/L and c-peptide \>0.2nmol/L, with a negative sulfonylurea screen
* At least 1 episode of glucose \<50mg/dL in the last year
4. Written informed consent obtained prior to treatment to be consistent with local regulatory requirements
5. No evidence of significant liver disease:

* Serum total bilirubin \< 2 x ULN
* INR \< 1.3 unless on anticoagulation
* ALT and AST \< 2 x ULN
* Alkaline phosphatase \< 2.5 x ULN
6. Patients receiving anti-hypoglycemic treatment are eligible
7. Patients who are treatment naïve, or those who were previously, but not currently, treated with anti-hypoglycemic therapy are also eligible
8. Patients with insulinoma who are operative candidates are eligible if surgery is not emergently needed, and study participation would not delay the timing of a surgical intervention

Exclusion Criteria

1. Age \<18, age \>70 (for both insulinoma and congenital hyperinsulinism)
2. Known hypersensitivity to somatostatin or analogues
3. Diabetic patients with poor glycemic control as evidenced by HbA1c \>8%
4. Patients who are hypothyroid and not on adequate replacement therapy
5. Patients with symptomatic cholelithiasis and acute or chronic pancreatitis
6. QTcF at screening \> 450 msec in males and QTcF \> 460 msec in females
7. Hypokalaemia, hypomagnesaemia, family history of long QT syndrome or concomitant medications with known risk of Torsades de pointes (TdP)
8. Patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, clinically significant bradycardia, advanced heart block, history of acute MI less than one year prior to study entry or clinically significant impairment in cardiovascular function
9. Severe non-malignant medical illness that may be jeopardized by treatment with a single dose of pasireotide
10. History of another primary malignancy, with the exception of locally excised non-melanoma skin cancer and carcinoma in situ of uterine cervix unless there is no evidence of disease in the last year
11. Patients with serum creatinine \>2.0 X ULN
12. Patients with WBC \<3 X 109/L; Hb 90% \< LLN; PLT \<100 X 109/L
13. Patients with the presence of active or suspected acute or chronic uncontrolled infection
14. Patients who have undergone major surgery/surgical therapy for any cause within 4 weeks prior screening
15. History of unexplained syncope or family history of idiopathic sudden death
16. Sexually active males unless they use a condom during intercourse while taking drug and for 3 months following last dose of pasireotide and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.
17. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
18. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and 30 days following last dose of pasireotide.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No